Study on How Genetic Mutations Affect Blood Clot Risk in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

What this Trial Is About

Researchers are investigating the link between genetic mutations and blood clot risks in patients with locally advanced or metastatic non-small cell lung cancer NSCLC. This observational study focuses on patients with or without specific oncogene mutations, such as EGFR, KRAS, ALK, ROS1, and PD-1PD-L1, to understand how these mutations relate to blood clotting factors and venous thromboembolism VTE events. The study aims to improve risk assessment tools for clotting complications in NSCLC. Patients diagnosed with NSCLC will be grouped based on the presence or absence of certain gene mutations. Blood samples will be collected before starting anticancer therapy, then again at 3 and 6 months, to measure clotting-related plasma factors like tissue factor, thrombin generation, and inflammatory markers. The study includes follow-up visits at enrollment, 3 months, and 6 months, or earlier if symptoms suggest a clotting event. During the study, participants will undergo blood testing and clinical evaluations to monitor clotting activity and detect any venous thromboembolism. Data collected will include cancer stage, genetic profiles, clotting factor levels, and recorded VTE events. Researchers will analyze these factors to understand clot risks and survival outcomes over a 6-month follow-up or until death, loss to follow-up, or withdrawal.

Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer